


CONCEPT ID 57669780 | GOSWAMI, KALER, PAI, SONG





655,000 PEOPLE SURVIVE A STROKE EACH YEAR IN AMERICA.

- over 2/3 of stroke patients require extensive rehab to regain function
- rehab costs \$27,473 per year on average, while the median US income is \$50,000



TRADITIONAL OUT-PATIENT REHABIS

generic. frustrating. ineffective.

and costs an average of \$3,314 per visit for a long-term motor function increase of only 14%.





US MARKET SIZE

- DISABLED STROKE SURVIVORS: 5 MILLION
- HAND DISABILTIES: 3 MILLION
- STROKES PER YEAR: 655 THOUSAND








EEG HEADCAP

which records patients' cerebullum brain signals

EXOTECH

solves these high-scale issues using a 4-facet solution



LSTM NEURAL NETWORKS

real-time predict the patient's intended motion from their brain signals



HAND EXOSKELETON

assists in executing the intended motion




MOBILE APP

Shows recovery data from exoskeleton sensors and facilitates doctor-patient communication.

04 | **SOLUTION**



prototype of hand exoskeleton modeled by exotech engineer






exotech app

CONNECTED • MOTIVATING • PROGRESSIVE









UNIQUEVALUE

	BCI	MOTIONS	SAFETY FEATURES	COST
NEOMANO	×	30		\$1999
SYREBO	×	5	×	\$199
SAEBOFLEX	×	1	×	\$600
EXOTECH		20		\$299

USER TRIALS

47.8% INCREASE

in range of motion

1.75x better than leading competiton

44.3% INCREASE

in grip strength

2.3x better than leading competition





PRICE MODEL

PER UNIT

COST OF GOODS

\$121.75

\$18 EEG Headcap

\$59 Biosensing Board

\$31.75 Exoskeleton

\$13 EEG Electrodes

MANUFACTURING & DISTRIBUTION

\$12.93

\$3.33 Labor

\$5.00 Overhead

\$1.40 Packaging

\$3.20 Distribution

RETAIL COST

\$299

55% margins will be re-routed back into the business for further development



LONG-TERM ROADMAP

Q2 2023

Exotech validated in a clinical trial with 20 patients and by stroke neurologists. Q4 2023

Following outreach, two rehab sites will trial our product on a large scale. Q1 2024

Started a crowdfunding campaign to raise \$100,000.

Q3 2024

6-month trials with committed rehab sites to gain market traction

Q1 2025


Entering market
B2B with contracts
in rehab centers
and hospitals

Q4 2029

Exit by being bought by a larger healthcare entity



FINANCIAL PROJECTIONS





"I am very impressed by the innovation Exotech brings to this field. Their brain-computer interface exoskeleton will revolutionize rehabilitation. With advanced motion tracking and intuitive software, Exotech delivers an accessible solution with verified efficacy. I fully endorse this technology."

Dr. Helmi Lutsep

Chair of Neurology at Oregon Health Science University



MEET THE TEAM



ARUSH GOSWAMI

Head of Research



JAZVEER KALER

Head of Software Development



AKASH PAI

Head of Product Development



ELEANOR SONG

Head of Marketing and Outreach

to revolutionize rehabilitation